Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
César Serrano
Led by VHIO’s César Serrano, alongside first author Jonathan C. Trent at the Sylvester Comprehensive Cancer Center in Miami, an…
After an initial response to approved tyrosine kinase inhibitors, principally imatinib, most patients with GIST will develop acquired cancer drug…
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
